Summary
Four human ovarian carcinoma xenografts were established and maintained in immune-suppressed mice. Cells obtained from these xenografts were exposed in vitro to melphalan, JM8, and cisplatin; cell survival following a 1-h exposure was measured using a soft-agar colony assay.
A similar dose-response curve was obtained with melphalan for each of the four xenografts, despite previous treatment with an alkylating agent in two of the patients from whom the xenografts originated. Cell survival was also compared after JM8 and cisplatin exposure in each individual xenograft. It was found to be similar for each tumour when the concentrations of JM8 used were 10-fold greater than those of cisplatin. Early clinical studies in which JM8 has been shown to be effective in the treatment of ovarian carcinoma support the view that xenograft tumours may have a role in phase-II screening of new cytotoxic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Chen HSG (1980) Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE (ed) Cloning of human tumour stem cells. Alan R Liss, New York, p 351
Bergman F (1966) Carcinoma of the ovary — A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 45:211
Bruckner HW, Cohen CJ, Goldberg JD et al. (1981) Improved chemotherapy for ovarian cancer with cis-diammine-dichloroplatinum and adriamycin. Cancer 47:2288
Calvert AH, Harland SJ, Newell DR et al. (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140
Cornbleet MA, Corringham RET, Prentice HG et al. (1981) Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 65:241
Cornbleet MA, McElwain TJ, Kumar PJ et al. (1983) Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 48:329
Courtenay VD (1976) A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer 34:39
Harland SJ, Newell DR, Siddick ZH et al. (1984) The pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II), (CBDCA) in patients with normal and impaired renal function. Cancer Res 44 (4)
Harrap KR, Jones M, Wilkinson CR et al. (1980) Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, current status and new developments. Academic Press, New York, p 193
McElwain TJ, Hedley DW, Burton G et al. (1979) Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer 40:72
Salmon SE, Hamburger AW, Soehnlen B et al. (1978) Quantitation of differential sensitivity of human-tumour stem cells to anticancer drugs. N Engl J Med 298:1321
Shorthouse AJ, Peckham MJ, Smyth JF, Steel GG (1980) The therapeutic response of bronchial carcinoma xenografts: A direct patient-xenograft comparison. Br J Cancer [Suppl IV] 41:142
Steel GG, Courtenay VD, Rostom AY (1978) Improved immune-suppression techniques for the xenografting of human tumours. Br J Cancer 37:224
Taetle R, Koessler AK, Howel SB (1981) In vitro growth and drug sensitivity of tumour-colony forming units from human tumour xenografts. Cancer Res 41:1856
Vermoken JB, Van Der Vijgh WJF, Klein I et al. (1982) Pharmacokinetics of free platinum species following rapid 3 hr and 24 hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18:1069
Wiltshaw E, Kroner T (1976) Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55
Wiltshaw E, Evans B, Jones AC et al. (1983) JM8, successor to cisplatin in advanced ovarian carcinoma? Lancet I:587
Young RC, Myers CE, Ozols RF, Hogan WM (1982) Chemotherapy in advanced disease. Int J Radiat Oncol Biol Phys 8:899
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, A.C., Wilson, P.A. & Gordon Steel, G. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8). Cancer Chemother. Pharmacol. 13, 109–113 (1984). https://doi.org/10.1007/BF00257125
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257125